33 related articles for article (PubMed ID: 15887951)
1. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.
Kreisel W; Schaffner D; Lazaro A; Trebicka J; Merfort I; Schmitt-Graeff A; Deibert P
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872119
[TBL] [Abstract][Full Text] [Related]
2. Targeting a Subpocket in Trypanosoma brucei Phosphodiesterase B1 (TbrPDEB1) Enables the Structure-Based Discovery of Selective Inhibitors with Trypanocidal Activity.
Blaazer AR; Singh AK; de Heuvel E; Edink E; Orrling KM; Veerman JJN; van den Bergh T; Jansen C; Balasubramaniam E; Mooij WJ; Custers H; Sijm M; Tagoe DNA; Kalejaiye TD; Munday JC; Tenor H; Matheeussen A; Wijtmans M; Siderius M; de Graaf C; Maes L; de Koning HP; Bailey DS; Sterk GJ; de Esch IJP; Brown DG; Leurs R
J Med Chem; 2018 May; 61(9):3870-3888. PubMed ID: 29672041
[TBL] [Abstract][Full Text] [Related]
3. Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
Miller MS; Maheshwari S; McRobb FM; Kinzler KW; Amzel LM; Vogelstein B; Gabelli SB
Bioorg Med Chem; 2017 Feb; 25(4):1481-1486. PubMed ID: 28129991
[TBL] [Abstract][Full Text] [Related]
4. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.
Cuadrado-Tejedor M; Garcia-Barroso C; Sánchez-Arias JA; Rabal O; Pérez-González M; Mederos S; Ugarte A; Franco R; Segura V; Perea G; Oyarzabal J; Garcia-Osta A
Neuropsychopharmacology; 2017 Jan; 42(2):524-539. PubMed ID: 27550730
[TBL] [Abstract][Full Text] [Related]
5. Revisiting Kadenbach: Electron flux rate through cytochrome c-oxidase determines the ATP-inhibitory effect and subsequent production of ROS.
Vogt S; Rhiel A; Weber P; Ramzan R
Bioessays; 2016 Jun; 38(6):556-67. PubMed ID: 27171124
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension.
Sae Yoon A; Sawatdee S; Woradechakul C; Sae Chee K; Atipairin A
Sci Pharm; 2015; 83(4):659-70. PubMed ID: 26839846
[TBL] [Abstract][Full Text] [Related]
7. Structural findings of cinnolines as anti-schizophrenic PDE10A inhibitors through comparative chemometric modeling.
Mondal C; Halder AK; Adhikari N; Jha T
Mol Divers; 2014 Aug; 18(3):655-71. PubMed ID: 24789056
[TBL] [Abstract][Full Text] [Related]
8. Advances in targeting cyclic nucleotide phosphodiesterases.
Maurice DH; Ke H; Ahmad F; Wang Y; Chung J; Manganiello VC
Nat Rev Drug Discov; 2014 Apr; 13(4):290-314. PubMed ID: 24687066
[TBL] [Abstract][Full Text] [Related]
9. Active site similarity between human and Plasmodium falciparum phosphodiesterases: considerations for antimalarial drug design.
Howard BL; Thompson PE; Manallack DT
J Comput Aided Mol Des; 2011 Aug; 25(8):753-62. PubMed ID: 21766240
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents.
Abadi AH; Abouel-Ella DA; Ahmed NS; Gary BD; Thaiparambil JT; Tinsley HN; Keeton AB; Piazza GA
Arzneimittelforschung; 2009; 59(8):415-21. PubMed ID: 19813465
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
Cullen MD; Cheung YF; Houslay MD; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
Bioorg Med Chem Lett; 2008 Feb; 18(4):1530-3. PubMed ID: 18222088
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide transcriptional profiling of the cyclic AMP-dependent signaling pathway during morphogenic transitions of Candida albicans.
Bahn YS; Molenda M; Staab JF; Lyman CA; Gordon LJ; Sundstrom P
Eukaryot Cell; 2007 Dec; 6(12):2376-90. PubMed ID: 17951520
[TBL] [Abstract][Full Text] [Related]
13. Cyclic nucleotide specific phosphodiesterases of Leishmania major.
Johner A; Kunz S; Linder M; Shakur Y; Seebeck T
BMC Microbiol; 2006 Mar; 6():25. PubMed ID: 16522215
[TBL] [Abstract][Full Text] [Related]
14. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Manallack DT; Hughes RA; Thompson PE
J Med Chem; 2005 May; 48(10):3449-62. PubMed ID: 15887951
[No Abstract] [Full Text] [Related]
15. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
[TBL] [Abstract][Full Text] [Related]
16. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
17. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.
Deninno MP; Andrews M; Bell AS; Chen Y; Eller-Zarbo C; Eshelby N; Etienne JB; Moore DE; Palmer MJ; Visser MS; Yu LJ; Zavadoski WJ; Michael Gibbs E
Bioorg Med Chem Lett; 2009 May; 19(9):2537-41. PubMed ID: 19339180
[TBL] [Abstract][Full Text] [Related]
18. Cyclic nucleotide phosphodiesterases. Possible targets for new drugs.
Polson JB
J Fla Med Assoc; 1990 Dec; 77(12):1045-6. PubMed ID: 1963437
[No Abstract] [Full Text] [Related]
19. [Phosphodiesterase inhibitor: griseolic acid, its' derivatives and their biological activities].
Kaneko M; Yamazaki M
Tanpakushitsu Kakusan Koso; 1995 Jul; 40(10):1268-76. PubMed ID: 7568925
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
